F
Fukang (Shanghai) Health Technology
Researcher and developer of innovative drugs focused on oncology treatments
About Fukang (Shanghai) Health Technology
Convalife (Shanghai) Health Technology Co., Ltd., operating as Convalife Pharmaceuticals, is a clinical-stage biopharmaceutical company established in 2015 with a focus on developing treatments for oncology, virology, and age-related diseases. The company was founded by Dr. Xiaokun Shen, who also serves as the chairman and CEO. Convalife operates with a global perspective, maintaining its headquarters in Shanghai and additional offices in Guangzhou and Boston.
The company's business model centers on the research and development of original drugs with "First-in-Class" or "Best-in-Class" potential to address unmet medical needs worldwide. Convalife has a robust pipeline that includes small molecule drugs and bispecific antibodies. Key products in development include CVL218, a second-generation PARP inhibitor, and CVL237, a highly selective PI3K β/δ dual inhibitor. The company's portfolio targets a range of cancers such as breast, lung, prostate, and pancreatic cancer, as well as various infectious diseases like COVID-19 and Respiratory Syncytial Virus (RSV). Revenue generation is driven by strategic partnerships, licensing agreements, and venture capital funding. The company has successfully raised significant capital through multiple funding rounds, including a Series C in January 2024 for $14 million.
Convalife has established numerous strategic collaborations to advance its pipeline. In August 2024, it partnered with Shanghai Henlius Biotech, granting them exclusive rights to commercialize neratinib (HANNAIJIA) in China for HER2-positive breast cancer treatment. This drug was approved by China's NMPA in June 2024. Another significant agreement was made in July 2022, when Convalife acquired the global rights for the PI3K β/δ inhibitor CVL-237 from Karus Therapeutics Ltd. The company also collaborates with other major entities like Hutchmed (China) Ltd. and Wuxi Biologics for combination therapies and development support, respectively.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jan 2024 | $14M | $55M | Xicheng Zhiyuan | ↗ |
| SPINOUT✓Other financing | Jan 2015 | $0 | — | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | — |
Growth signals
Latest recorded traffic for Fukang (Shanghai) Health Technology is 180 monthly website visits, up 20% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Fukang (Shanghai) Health Technology in its local ecosystem
The Fukang (Shanghai) Health Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Xicheng Zhiyuan
Other known investors1 additional known investor
- SSShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fukang (Shanghai) Health Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fukang (Shanghai) Health Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









